10x Genomics (TXG) Non-Current Assets (2018 - 2026)

10x Genomics has disclosed Non-Current Assets across 9 years of filings, most recently posting $355.4 million for Q2 2026.

• In Q2 2026, Non-Current Assets rose 9.59% year-over-year to $355.4 million; the TTM figure through Jun 2026 stood at $1.4 billion (up 7.52% YoY), while the FY2025 annual figure was $356.9 million, up 6.78% from the prior year.
• Non-Current Assets came in at $355.4 million for Q2 2026 at 10x Genomics, up from $346.0 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $412.1 million in Q1 2023 to a low of $305.9 million in Q1 2022.
• Average Non-Current Assets over 5 years is $357.5 million, with a median of $355.6 million recorded in 2024.
• Year-over-year, Non-Current Assets soared 52.16% in 2022 and retreated 13.81% in 2024.
• Over 5 years, Non-Current Assets stood at $393.9 million in 2022, then decreased by 6.3% to $369.1 million in 2023, then declined by 9.45% to $334.2 million in 2024, then rose by 6.78% to $356.9 million in 2025, then dropped by 0.43% to $355.4 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $355.4 million in Q2 2026, $346.0 million in Q1 2026, and $356.9 million in Q4 2025.